ClinicalTrials.Veeva

Menu

Influenza Vaccine in HIV Study

U

University of Melbourne

Status

Completed

Conditions

Influenza, Human

Treatments

Biological: 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)

Study type

Observational

Funder types

Other

Identifiers

NCT02632578
Kent001
1041832, 1042634, 1052979 (Other Grant/Funding Number)
AISRF08020 (Other Grant/Funding Number)

Details and patient eligibility

About

The aims of this study are:

  1. to investigate if HIV infection alters the antibody responses to influenza and
  2. to assess the ability of licensed influenza vaccine to induce functional non-neutralising antibodies in HIV-infected and HIV-uninfected subjects.

Enrollment

57 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • HIV-1 positive by licensed diagnostic test (for HIV-positive group only)
  • Planning to receive the seasonal influenza vaccine outside the study
  • Provision of written informed consent

Exclusion criteria

  • Previous allergy to influenza vaccination
  • Pregnancy or planning to become pregnant
  • Unwilling or unable to provide blood samples

Trial design

57 participants in 2 patient groups

HIV-positive
Treatment:
Biological: 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)
HIV-negative
Treatment:
Biological: 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems